Nicola Normanno

Oncologia Sperimentale D, ITN-Fondazione Pascale, Italy

Any competing interests declared are displayed with individual evaluations.

Faculty Member: Oncology > Oncology Agents (since 14 November 2005)

All recent recommendations

• 6.4
  K-ras mutations and benefit from cetuximab in advanced colorectal cancer.
  Recommended by Nicola Normanno with Antonella De Luca, Jeffrey Evans
  
• 3.0
  Identification of secreted proteins that mediate cell-cell interactions in an in vitro model of the lung cancer microenvironment.
  Recommended by Nicola Normanno with Antonella De Luca
  
• 9.8
  The epithelial-mesenchymal transition generates cells with properties of stem cells.
  Recommended by Nicola Normanno with Antonella De Luca, Carlos Telleria, Larry Suva with Corey O Montgomery
  
• 6.0
  KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.
  Recommended by Nicola Normanno
  
• 8.3
  Mesenchymal stem cells within tumour stroma promote breast cancer metastasis.
  Recommended by Florence Apparailly, Paul Simmons with Jeannie Javni, Larry Suva, Nicola Normanno
  
• 3.0
  Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation.
  Recommended by Nicola Normanno
  
• 6.6
  Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
  Recommended by Debu Tripathy, Daniel Vorobiof, Nicola Normanno
  
• 6.0
  Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3.
  Recommended by Nicola Normanno
  
• 6.0
  HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors.
  Recommended by Nicola Normanno
  
• 3.0
  Heparan sulphate proteoglycans are essential for the myeloma cell growth activity of EGF-family ligands in multiple myeloma.
  Recommended by Nicola Normanno
  
• 3.0
  Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.
  Recommended by Nicola Normanno
  
• 3.0
  Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation.
  Recommended by Nicola Normanno
  
• 3.0
  Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis.
  Recommended by Nicola Normanno